R&D | January 14, 2026
Zealand Pharma taps Denmark’s supercomputer to supercharge drug discovery
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Subscribe To Our Newsletter & Stay Updated
